The latest price target for Allogene Therapeutics (NASDAQ:ALLO) was reported by JP Morgan on October 10, 2025. The analyst firm set a price target for $0.00 expecting ALLO to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Allogene Therapeutics (NASDAQ:ALLO) was provided by JP Morgan, and Allogene Therapeutics downgraded their underweight rating.

The last upgrade for Allogene Therapeutics Inc happened on March 14, 2025 when Citizens Capital Markets raised their price target to $5. Citizens Capital Markets previously had a market perform for Allogene Therapeutics Inc.

The last downgrade for Allogene Therapeutics Inc happened on October 10, 2025 when JP Morgan changed their price target from N/A to N/A for Allogene Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on October 10, 2025 so you should expect the next rating to be made available sometime around October 10, 2026.

While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Allogene Therapeutics (ALLO) is trading at is $1.53, which is out of the analyst’s predicted range.